Granules India Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, showcasing strong performance across both standalone and consolidated operations. The pharmaceutical company's Board of Directors approved these results at their meeting held on January 23, 2026.

Consolidated Financial Performance

The company delivered robust consolidated results for Q3 FY26, demonstrating strong operational efficiency across its global operations.

For the nine months ended December 31, 2025, consolidated revenue reached ₹38,950.34 million compared to ₹32,841.79 million in the corresponding period, marking significant year-over-year growth. Net profit for the nine-month period stood at ₹3,934.53 million versus ₹3,494.85 million in the previous year.

Standalone Results Analysis

The standalone financial performance also reflected strong fundamentals, with the company maintaining healthy margins despite operational challenges.

The nine-month standalone revenue totaled ₹25,971.39 million compared to ₹22,621.37 million in the previous year, with net profit reaching ₹3,016.80 million against ₹2,252.82 million.

Operational Developments and Challenges

The company faced regulatory challenges during the period, with the Gagillapur facility receiving a USFDA warning letter in February 2025 following an inspection during August-September 2024. In response, Granules voluntarily paused manufacturing and distribution operations at the facility during September 2024 to conduct comprehensive risk assessments and address USFDA inspection observations.

The company has initiated a comprehensive remediation plan involving three independent consultants to enhance existing procedures and implement new protocols. This situation impacted revenue due to production slowdown and increased expenses, primarily consultancy costs and air freight charges.

Strategic Acquisitions and Expansion

Granules continued its expansion strategy through strategic acquisitions during the period:

Exceptional items for the nine months included transaction costs of ₹121.60 million related to the Senn Chemicals AG acquisition, alongside settlements of ongoing litigations and investment disposal gains.

Capital Raising Initiatives

The Board of Directors and shareholders approved significant capital-raising measures during the period. The company plans to raise funds through issuance of up to 25,000,000 convertible warrants at ₹585.00 per warrant, aggregating up to ₹14,625.00 million. Additionally, the company will issue up to 5,128,205 fully paid equity shares at ₹585.00 per share, totaling ₹3,000.00 million.

These capital-raising initiatives are subject to regulatory approvals and will support the company's growth strategy and operational expansion plans. The convertible warrants will be convertible into equivalent equity shares within 18 months from the allotment date.

Granules India Limited has announced its earnings conference call for the third quarter of FY26, scheduled for January 23, 2026 at 6:00 PM IST. The pharmaceutical company will discuss its financial performance and provide business updates during the analyst and investor call.

Conference Call Details

The earnings call has been scheduled under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided multiple access options for participants, including domestic and international dial-in numbers.

Key Participants

The earnings call will feature senior leadership from Granules India, providing comprehensive insights into the company's quarterly performance. The management team includes key executives from various operational areas.

Access Information

Participants can join the conference call through multiple channels, with both domestic and international access numbers provided. The company has also arranged for pre-registration to streamline the process.

Company Profile

Granules India Limited operates in the pharmaceuticals sector and is classified as a mid-cap company with a market capitalization of ₹13,840.60 crores. The company is listed on both NSE (symbol: GRANULES) and BSE (code: 532482), with its registered office located in Hyderabad, Telangana.

The scheduled earnings call represents the company's commitment to maintaining transparency and regular communication with stakeholders regarding its financial performance and strategic developments.